<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712554</url>
  </required_header>
  <id_info>
    <org_study_id>CLCT-007</org_study_id>
    <nct_id>NCT02712554</nct_id>
  </id_info>
  <brief_title>A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charleston Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charleston Laboratories, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the abuse potential of CL-108 tablets, including the
      abuse deterrent effects of promethazine, following oral administration, relative to
      hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid
      users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the abuse potential of CL-108 tablets, including the
      abuse deterrent effects of promethazine, following oral administration, relative to
      hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid
      users; to assess the cognitive and behavioral effects of CL-108 tablets following oral
      administration relative to hydrocodone/APAP tablets and placebo in non-dependent,
      recreational opioid users; and to assess the safety of orally administered CL-108 tablets
      relative to hydrocodone/APAP tablets and placebo in non-dependent, recreational opioid users.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum effect (Emax) of Drug Liking VAS</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pain</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Treatment A low dose CL-108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 tablets, 22.5mg hydrocodone, 975 mg APAP, 37.5 mg promethazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B high dose CL-108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL 108, 37.5 mg hydrocodone, 1625 mg APAP, 62.5 mg promethazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C low dose M366</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M366 tablets, 22.5 mg hydrocodone/975mg APAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D high dose M366</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M366 tablets, 37.5 mg hydrocodone, 1625 mg APAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A low dose CL-108</intervention_name>
    <description>Treatment A low dose CL-108</description>
    <arm_group_label>Treatment A low dose CL-108</arm_group_label>
    <other_name>22.5mg hydrocodone,975 mg APAP,37.5 mg promethazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B high dose CL-108</intervention_name>
    <description>Treatment B high dose CL-108</description>
    <arm_group_label>Treatment B high dose CL-108</arm_group_label>
    <other_name>CL 108 37.5 mg hydrocodone,1625 mg APAP,62.5 mg promethazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C low dose M366</intervention_name>
    <description>M366 Low Dose</description>
    <arm_group_label>Treatment C low dose M366</arm_group_label>
    <other_name>M366 22.5 mg hydrocodone/975mg APAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D high dose M366</intervention_name>
    <description>M366 High Dose</description>
    <arm_group_label>Treatment D high dose M366</arm_group_label>
    <other_name>M366 37.5 mg hydrocodone, 1625 mg APAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI within 18.0 to 33.0 kg/m2, inclusive (minimum weight of 50.0 kg at Screening)

          -  Healthy, as determined by no clinically significant medical history, physical
             examination findings, 12-lead ECG findings, vital signs measurements, and laboratory
             results at screening, as judged by the investigator

          -  Current opioid users who had used oral opioids for recreational (non-therapeutic)
             purposes, at least 10 times in the past year

        Exclusion Criteria:

          -  Drug or alcohol dependence within the last 12 months (except nicotine)

          -  Subjects who had ever been in treatment for substance use disorders (except smoking
             cessation

          -  History of presence of any clinically significant cardiac, neurologic, pulmonary,
             psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic,
             dermatologic, renal, or other major disease at screening, which in the opinion of the
             investigator, would have jeopardized the safety of the subject or the validity of the
             study results

          -  History or presence of hypotension, judged to be clinically significant based on
             investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 14, 2016</submitted>
    <returned>January 11, 2017</returned>
    <submitted>January 27, 2017</submitted>
    <returned>March 21, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

